Published on
March 10, 2016
- 21:01 GMT
Flexion Reports Year-End 2015 Financial Results
Pivotal registration trials completed in patients with osteoarthritis (OA) of the knee for Zilretta™, Flexion’s lead drug candidate (also known as FX006) Zilretta received Fast-Track designation by U.S. Food & Drug Administration (FDA) in 2015; planned …
Distribution channels:
Banking, Finance & Investment Industry, Conferences & Trade Fairs
...
